GuiChao Life Files IPO Prospectus: Delivering an Integrated, Personalized, and Private Women's Health Management Solution
According to Sullivan’s statistics, the market size of women’s health management platforms grew from RMB 510 million in 2013 to RMB 13.0 billion in 2018, representing a compound annual growth rate (CAGR) of 91.3%, and is projected to reach RMB 47.17 billion by 2024.
The vast development prospects have made the women’s health management market a fertile ground for entrepreneurship, attracting numerous companies to establish their presence in niche sectors such as reproductive health, clinical care for women, and oocyte cryopreservation, thereby giving rise to many successful women’s health management enterprises.
The women’s health management industry has seen steadily rising interest year by year, with a plethora of products available. However, Tang Li, founder of Guichao Life, believes that the current health management market fails to meet the needs of the new generation of women. “There is still a lack of solutions in the market that truly adopt a woman-centric perspective and provide systematic, personalized, and privacy-conscious health management across the entire life cycle.”
In recent years, driven by emerging technologies such as big data, artificial intelligence, and molecular diagnostics, solutions for women’s health management have become increasingly personalized and precise. GuiChao Life is a healthcare company that leverages innovative technologies to focus on high-incidence cancers in women and reproductive health, providing full-lifecycle health management and precision medicine services for women.
Guichao Life leverages molecular diagnostic reagents as its entry point, integrating modern medicine and technological tools to construct AI-driven big data profiles for women. By relying on its proprietary genetic testing technology and a multi-dimensional, multi-omics detection platform, and by combining these with clinical phenotype data and follow-up data on drug efficacy, the company is committed to linking genetic data, clinical follow-up data, and medication data. This approach establishes a tripartite closed-loop clinical system for precision diagnosis and treatment, providing personalized, precise health and therapeutic solutions for women.
Tang Li, founder of Guichao Life, has years of experience in the field of assisted reproductive technology and specializes in women’s health management consulting services, demonstrating profound insights into women’s health management needs.
Guichao Life targets the new generation of female consumers born in the 1980s and 1990s. Tang Li stated that this demographic affirms their self-worth, pursues economic and intellectual independence, and demonstrates high acceptance of new technologies and products. In addition to focusing on the functional attributes of health management products, they place greater emphasis on subsequent supporting services. Tang Li believes thatSystematic, Personalized, and PrivateThese are the three essential needs of the new generation of women for health management products. Centered on these three demands, Guichao Life has launched corresponding solutions.
In terms of systematization,Guichao Life has established an online platform, opened offline medical institutions, and assembled a team of healthcare professionals. By integrating online and offline services, it offers women’s health management solutions that cover home-based screening, diagnosis and treatment, and home rehabilitation.Establish a closed-loop system for women's health management integrating prevention, diagnosis, treatment, and online-offline services.
Guichao Life: A One-Stop Solution for Women’s Health Management
In terms of personalization,Guichao Life constructs comprehensive health profiles by analyzing women’s health data across different life stages, including genetic information, clinical follow-up records, and medication history. It assembles a dedicated “5-to-1” health management team—comprising tertiary hospital medical experts, health assistants, nutritionists, professional fitness coaches, and licensed nurses from tertiary hospitals—to deliver personalized health management plans tailored to each user.
In terms of privacy,Guichao Life adopts a home-based screening model, leveraging the privacy features of the internet. Users place orders online and then utilize either self-sampling or in-home sampling by healthcare professionals, enabling convenient sample collection without leaving home and online access to reports. This approach not only meets users’ privacy needs but also reduces the time cost associated with off-site medical consultations and conserves hospital medical resources.
Currently, Guichao Life is primarily focused on cancers with high incidence in women and has already launchedHPV Testing Products、Breast Cancer Detection Products, andColorectal Cancer Detection ProductsAccording to the latest 2020 global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer, colorectal cancer, and cervical cancer ranked first, second, and fourth, respectively, among the top ten most common newly diagnosed cancers in women worldwide. Undoubtedly, breast cancer, colorectal cancer, and cervical cancer have become major threats to women's health.
HPV Genotyping Genetic Testing Product
Guichao Life’s tumor screening products feature high sensitivity, high specificity, and convenience. Integrated with the company’s one-stop solution for women’s health management, these products enable home-based sample collection, conserve medical resources, and establish an effective triage mechanism for positive cases. This approach enhances screening coverage and ensures effective management of positive patients, representing a tumor screening model better suited to China’s current national conditions.
Currently, Guichao Life’s one-stop health management solution for women has entered the market, with strategic partnerships established with over 30 channel partners, reaching a female customer base of more than 7 million. The company has contracted 6,000 licensed nurses and over 10 obstetrics and gynecology specialists.
With rising health awareness among women, growing purchasing power, and favorable policy support, China’s female health management market has demonstrated broad prospects. The Outline of the “Healthy China 2030” Plan emphasizes “health for all,” prioritizing prevention, strengthening early diagnosis, early treatment, and early rehabilitation, and carrying out early screening and treatment for major cancers in high-incidence areas. Since 2009, China has implemented a cervical and breast cancer screening program for rural women. The Healthy China Action (2019–2022) further stipulates that by 2022, the coverage rate of cervical and breast cancer screening for eligible rural women should reach 80% at the county/district level.
Meanwhile, driven by technologies such as artificial intelligence and big data, China’s health management market is exhibiting personalized characteristics. Tang Li believes that,Personalization, refinement, and intelligence will be the future development trends in the women's health management market.Guichao Life will increase its investment in and utilization of AI and big data to build more precise and personalized health management solutions.
Tang Li also noted that low market awareness remains a significant barrier to the development of China’s women’s health management market. It is reported that 80% of women in China suffer from gynecological diseases without being aware of their condition. Moving forward, Guichao Life will focus its efforts on promoting women’s health management solutions and strengthening market education initiatives.
Furthermore, Guichao Life has also recognized the potential of the family health management market. In the future, the company’s target audience will expand from women to entire families, providing a closed-loop comprehensive health management service for more family members, including children and the elderly.